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Background: Patients in cardiogenic shock beneﬁt from mechanical reperfusion, but
their mortality remains high even using intra-aortic balloon. It is not well known if
a Mechanical Circulatory Support Program (MCSP) might improve the long term
outcome of these patients.
Methods: We have compared in-hospital and 1 year survival of patients in cardio-
genic shock in the setting of a primary angioplasty with inserted intra-aortic balloon in
two different periods of time, before and after the implementation in our hospital of
a MCSP. This program included training for staff and the availability of extracorporeal
membrane oxygenation device (ECMO) and left ventricular or biventricular assist
devices (LVAD, biVAD). Following inclusion criteria were required: STEMI,
cardiogenic shock by deﬁned clinical and hemodynamic data, primary angioplasty
done and intra-aortic balloon inserted. Patients with cardiogenic shock due to
mechanical complications were excluded.
Results:We included 42 consecutive patients in the ﬁrst period "pre-MCSP" and 56 in
the second period "post-MCSP". Clinical baseline characteristics were very similar in
both groups except for a higher use of drug-eluting stents in the second period (19% vs
40%; p¼0.03). In the "post-MCSP" group 9 (16%) patients had an ECMO and 8
(14.3%) a ventricular assist device. Six patients were included in the cardiac transplant
list in the "pre-MCSP" group and four in the "post-MCSP" group. Three patients in
each group ﬁnally underwent a cardiac transplant. In-hospital survival was 49.9% in
the "pre-MCSP" group compared to 67.2% in the "post-MCSP" group (p¼0.03). The
12 months survival was 39,8% in the "pre-MCSDP"group vs. 59.5% in the "post-
MCSP" group (p¼0.03). The multivariate logistic regression revealed a higher risk of
death in the "pre-MCSP" period (HR 2.5;CI 95% 1.04-7.5:p¼ 0.04).
Conclusions: The implementation of a mechanical circulatory support program
improves signiﬁcantly the prognosis of patients in cardiogenic shock in the setting of
a primary angioplasty.
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Percutaneous atrioseptostomy is a safe and efﬁcient strategy for left heart
discharge under veno-arterial peripheral extracorporeal membrane oxygenation
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Background: Veno-arterial Extracorporeal Membrane Oxygenation (VA-ECMO) is
a life-saving mechanical support in case of intractable heart failure. It is widely used in
both children and adult patients, as a bridge to recovery or heart transplantation. It can
lead to increased left atrial pressure, resulting in haemoptysis and severe acute
pulmonary oedema. We hypothesized that percutaneous atrioseptostomy (PAS) is
a safe and efﬁcient alternative for left heart discharge under VA-ECMO.
Methods: A monocenter retrospective study was conducted at our center From April
2008 to April 2013, 160 patients were assisted with peripheral VA-ECMO. Twenty-
three of them (1 month to 72 years old, median age: 34 years, 6 children and 17 adults)
needed left heart discharge and had a PAS. The procedure was done in the cathe-
terization laboratory under ﬂuoroscopic guidance via the femoral vein and a trans-
septal puncture using a Brockenbrough needle. For adult patients, a 28 mm Inoue
balloon was inﬂated across the inter-atrial septum, creating an unrestrictive 30 mm
atrial septal defect. Left and right atrial pressures were measured in the cath lab before
and just after PAS.
Results: Intractable heart failure was due to acute myocarditis (n¼5), dilated
cardiomyopathy (n¼9), acute coronary syndrome (n¼4) or post-operative myocardial
dysfunction (n¼5). PAS was performed under local anaesthesia in 9 patients (40%).
Median delay from ECMO to PAS was 64 hours (4 to 766 hours). No procedure-
related complication was reported. Left atrial pressure signiﬁcantly decreased after
atrioseptostomy, from 22mmHg (5 to 45 mmHg) to 10mmHg (1 to 19 mmHg),
p<0,001. Clinical improvement was observed in 4 of 6 patients with pulmonary
haemorrhage and 18 of 22 patients with pulmonary oedema (81, 8%, IC95%[65.7%-
97.9%]). At a mean follow-up of 8.3 9, 2 days after the procedure, two patients were
successfully weaned from ECMO, 4 patients had implantation of a left ventricular
assist device, 8 were transplanted and 9 patients died under VA-ECMO.
Conclusions: PAS is a safe and efﬁcient strategy to discharge the left heart in
paediatric and adult patients under peripheral VA-ECMO.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-438
Alcohol septal ablation (ASA) for hypertrophic obstructive cardiomyopathy
(HOCM) - follow up to 12 years.
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Background: ASA is an established treatment for symptomatic HOCM. The evidence
base is limited to case series. ASA has a 2b recommendation in treatment for HOCM
from the 2011 ACCF/AHA guidelines. We report a series over 12 years from a high
volume UK centre.
Methods: All patients referred to our tertiary centre for ASA from 2000-2012 were
reviewed. All had peak LVOT gradient 50mmHg and basal septal diameter >15mm.
No patient had systolic dysfunction. Only those entering the lab with the intention of
alcohol delivery were included. 88 patients were identiﬁed, mean age 60.3 years. Four
patients could not receive alcohol. 20 (24%) required a second procedure with
delivery of alcohol, 2 (2%) required a third. Follow up period was 4.2 (+/-3.3) years,
range 0.13-12.29.
Results: Mean number of arteries injected was 1.13 (+/-0.37), volume of alcohol
used was 2.24 (+/-1.08) mL. CK-MB release was 149.6 (+/-135.6) ng/dL. New CHB
requiring PPM was seen in 14/74 (17%) patients. One inpatient death followed
haemodynamic compromise as a complication of PPM implant. Distal infarction of
inferior wall was seen in 1, pericardial effusion without tamponade in 1. Symp-
tomatic follow up was available in 82/84 patients. Mean NYHA class dropped from
2.80 (+/-0.46) to 1.92 (+/-0.84)(p<0.0001). 72% patients improved, 26% found no
difference, 2% deteriorated. CPEX testing pre and post-ASA with RER >1.1 was
available in 24. Peak VO2 improved from 18.9 (+/-4.45) to 20.09 (+/-5.73) ml/min/
kg (p¼0.018). Pre and post echocardiographic assessment was available in 74. 61
had rest LVOT gradient of >50mmHg, peak 99.8 (+/-46.1)mmHg. Post ASA
gradient reduced to 23.9 (+/-41.6)mmHg (p<0.0001). A further 13 patients had
minimal resting gradient but >50mmHg on exercise, peak value 102.0 (+/-49.6)
mmHg. This improved to 16.9 (+/-30.7)mmHg (p¼0.0005). Failure was deﬁned as
ﬁnal gradient >50mmHg or reduction in gradient <50%. This occurred in 13/74
(18%). No sudden death was observed. No appropriate therapy was delivered in 15
with ICD.
Conclusions: ASA provides symptomatic improvement and gradient resolution for
the majority. However; 5% do not receive treatment, 18% have failure to resolve
LVOT gradient and 28% ﬁnd no improvement in dyspnoea.TCT-439
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Background: Left ventricle (LV) remodeling after anterior wall myocardial infarction
(AWMI) leads to increased LV volumes, myocardial stress, and ultimately heart
failure (HF). Treatment options are limited for these high-risk HF patients. First-in-
man (FIM) experience of PVR using the Parachute device suggested the safety of
this approach. An ongoing study was designed to validate these observations in an
independent cohort of patients.
Methods: To conﬁrm the short term and long term efﬁcacy of PVR using an expanded
range of Parachute device sizes in patients with ischemic HF with prior AWMI.
Methods: Up to 80 patients with NYHA class II-IV HF secondary to AWMI, with
akinetic or dyskinetic wall motion abnormality, LV ejection fraction <40%, and
without the need for revascularization are being enrolled into this prospective study at
20 European sites. Primary endpoint Major endpoints to report are device-related
MACE and death plus hospitalization for worsening heart failure (WHF). A subset of
patients (approximately 15) underwent repeat CT imaging at 6 months post implant.
Results: As of May 9, 2013, 55 patients had reached 6 month FU and 26 patients
had reached 12 month FU. Historical 6-month and 12-month rates of death + WHF
for the FIM cohort was 16.1% and 16.1%, respectively. In the present Validation
cohort, the 6 month and 12 month rates of death + WHF was 18.9% and 23.7%,
respectively. Additionally, the paired CT images will be analyzed and compared to
the FIM subset of CT imaging. Follow-up on 80 patients at 6 month and 50
patients at 12 month will be completed by September 1, 2013 and results will be
available for presentation.
Conclusions: Preliminary results of this conﬁrmatory trial of PVR using an expanded
range of Parachute device sizes in an independent cohort of patients with ischemic HF
and prior AWMI supports the safety and efﬁcacy of Parachute, thus supporting the
conduct of a large RCT.acts/POSTER/Circulatory Support, Heart Failure, and HOCM B135
